{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:43:50Z","timestamp":1788507830772,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cllc.2022.07.008","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T02:40:40Z","timestamp":1658371240000},"page":"720-730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK\u2013Inhibitor-Naive ALK+ Non\u2013Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study"],"prefix":"10.1016","volume":"23","author":[{"given":"Myung J.","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye R.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacky Yu-Chung.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian J.","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Delmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario G.","family":"Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Gridelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmistha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingkuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.07.008_bib0001","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.07.008_bib0002","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.07.008_bib0003","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2022.07.008_bib0004","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4143\/crt.2017.280","article-title":"Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer","volume":"50","author":"Nishio","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.cllc.2022.07.008_bib0005","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.008_bib0006","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.008_bib0007","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2022.07.008_bib0008","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.008_bib0009","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.008_bib0010","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib versus crizotinib in advanced ALK inhibitor\u2013naive ALK-positive non\u2013small cell lung cancer: Second interim analysis of the phase III ALTA-1L trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.008_bib0011","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: Final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.008_bib0012","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.008_bib0013","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","article-title":"Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in east asian patients with ALK-positive advanced non-small cell lung cancer","volume":"13","author":"Wu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.008_bib0014","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2022.07.008_bib0015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.07.008_bib0016","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer","volume":"36","author":"Solomon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.008_bib0017","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1073\/pnas.1019559108","article-title":"Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK","volume":"108","author":"Katayama","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cllc.2022.07.008_bib0018","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase","volume":"59","author":"Huang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.cllc.2022.07.008_bib0019","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: A single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2022.07.008_bib0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2022.07.008_bib0021","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/cts.13231","article-title":"Population pharmacokinetic and exposure-response analyses from ALTA-1L: model-based analyses supporting the brigatinib dose in ALK-positive NSCLC","volume":"15","author":"Gupta","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.cllc.2022.07.008_bib0022","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1200\/JCO.2019.37.15_suppl.9026","article-title":"Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial [abstract]","volume":"37","author":"Ahn","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.008_bib0023","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtho.2019.11.004","article-title":"Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial","volume":"15","author":"Huber","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"suppl 10","key":"10.1016\/j.cllc.2022.07.008_bib0024","doi-asserted-by":"crossref","first-page":"x191","DOI":"10.1093\/annonc\/mdx729.009","article-title":"Alectinib (ALC) vs. crizotinib (CRZ) in treatment-na\u00efve ALK+ non-small-cell lung cancer (NSCLC): Asian vs. non-Asian subgroup analysis of the ALEX study [abstract 410O_PR]","volume":"28","author":"Mok","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422001528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422001528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:13:19Z","timestamp":1761505999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422001528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1525730422001528"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.008","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK\u2013Inhibitor-Naive ALK+ Non\u2013Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}